REGENXBIO Inc. announced on May 19, 2025, the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250 million with Healthcare Royalty (HCRx). The company received $150 million at closing, which extends its expected cash runway into early 2027.
Under the terms, HCRx will receive rights to anticipated royalty payments from sales of ZOLGENSMA, as well as royalty and certain milestone payments from RGX-121 and RGX-111 through the Nippon Shinyaku partnership, and other NAV Technology Platform licensees.
REGENXBIO retains other future potential non-dilutive funding sources, including the potential sale of the expected Priority Review Voucher for RGX-121 and development and sales milestones from AbbVie. This financing provides capital to accelerate commercial preparations and advance its differentiated portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.